Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for plerixafor injection single-dose vial product. 

The product is bio-equivalent and therapeutically equivalent to the reference listed drug Mozobil (plerixafor) from Genzyme Corporation, a Sanofi company. 

It is a haematopoietic stem cell mobiliser indicated in combination with filgrastim to mobilise haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma. 

The Hyderabad-based company expects to launch the product through its marketing partner in FY25. According to IQVIA, the product had US sales of approximately $152 million for the 12 months ending January 2024, a release said.

Also read
Packaged spices of MDH and Everest brands are under the lens of food safety regulators in Hong Kong and Singapore

Australian food safety regulator examines Indian spice recall issue

Glenmark Pharmaceuticals receives ANDA approval for acetaminophen and ibuprofen tablets

Related Topics
comment COMMENT NOW